UC Research Reveals Key Cellular Function
The same enzyme that ensures cells undergo normal, programmed death is also necessary for proper formation of the embryo, according to an article that appeared in a December issue of the
Proceedings of the National Academy of Sciences
(PNAS).
Without programmed death, or apoptosis, cells would continue to proliferate indefinitely, leading to cancerous tumors. During programmed or normal cell death, a series of events leads to the eventual consumption of the cell by roving sentinels. One important step is the release of an enzyme called endonuclease G from the mitochondria inside the cell and its transport to the nucleus of the cell where it cleaves apart the DNA and the cell dies.
Jianhua Zhang, PhD, and Ming Xu, PhD, both faculty members at the UC Department of Cell Biology, Neurobiology and Anatomy, and colleagues investigated the role of this enzyme by developing strains of mice that were unable to produce the enzyme endonuclease G. Mice missing one copy of the gene had cells that were resistant to normal cell death or apoptosis.
Although this enzyme has been implicated in the replication of mitochondrial DNA, the numbers of mitochondrial DNA were the same in mutant and wild-type mice. Interestingly, the researchers were unable to produce mice missing both copies of the endonuclease G gene. Dr. Zhang and Dr. Xu said endonuclease G may play an essential role in remodeling the structure of the developing embryo through apoptosis, from a solid ball of cells to a hollow one that is not viable.
Dr. Zhang and Dr. Xu's research study demonstrates how this enzyme confers life and death. Results of their study were reported in the PNAS article #03-6393 and titled "Endonuclease G is required for early embryogenesis and normal apoptosis in mice."
Tags
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.